A Snapshot of Real-World TAVR Results

In a French registry study, outcomes were similar to those in the PARTNER trial.

Recent publication of the PARTNER randomized trial findings (JW Cardiol Sep 22 2010) led to FDA approval of transcatheter aortic-valve replacement (TAVR) in the U.S. To monitor how TAVR is used in clinical practice, investigators in France established an industry-funded national registry among 34 authorized centers and now report on 3195 patients (mean age, 83; 49% women) who underwent TAVR between January 2010 and October 2011. Median follow-up was 114 days and 99.8% complete.

All patients were high-risk, with a mean Society of Thoracic Surgeons 30-day mortality estimate of 14.4%. Most (75%) procedures were performed in cardiac catheterization laboratories with SAPIEN (67%) or CoreValve (33%) devices inserted via transfemoral (75%), transap…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)